James E. Peacock Jr., MD; Deirdre A. Herrington, MD; James C. Wade, MD; Hillard M. Lazarus, MD; Michael D. Reed, MD; Jane W. Sinclair, RN; Daniel C. Haverstock, MS; Steven F. Kowalsky, PharmD; David D. Hurd, MD; Deborah A. Cushing, RN; Colleen P. Harman, RN; Gerald R. Donowitz, MD
Empirical therapy with an aminoglycoside and a β-lactam remains common for febrile neutropenic patients. Concerns about aminoglycoside-induced ototoxicity and nephrotoxicity have led to studies of alternate regimens. In this study, ciprofloxacin–piperacillin was as safe and effective as tobramycin–piperacillin for empirical therapy of neutropenic fever.
Ann Intern Med. 2002;137(2):77-87. doi:10.7326/0003-4819-137-2-200207160-00005
Harry P. Selker, MD, MSPH; Joni R. Beshansky, RN, MPH; John L. Griffith, PhD; for the TPI Trial Investigators*
Although its effect was minimal on patients with high baseline reperfusion rates, the electrocardiograph-based Thrombolytic Predictive Instrument increased use and timeliness of reperfusion in often-missed groups and when involved physicians were off site.
Ann Intern Med. 2002;137(2):87-95. doi:10.7326/0003-4819-137-2-200207160-00006
Michael Pignone, MD, MPH; Somnath Saha, MD, MPH; Tom Hoerger, PhD; Jeanne Mandelblatt, MD, MPH
Screening for colorectal cancer appears cost-effective compared with no screening, but a single optimal strategy cannot be determined from the currently available data. Additional data and additional analyses are necessary.
Ann Intern Med. 2002;137(2):96-104. doi:10.7326/0003-4819-137-2-200207160-00007
Philip C. Johnson, MD; L. Joseph Wheat, MD; Gretchen A. Cloud, MS; Mitchell Goldman, MD; Dan Lancaster, MD; David M. Bamberger, MD; William G. Powderly, MD; Richard Hafner, MD; Carol A. Kauffman, MD; William E. Dismukes, MD; for the U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group*
In patients with moderate to severe histoplasmosis associated with AIDS, the preferred treatment has been the deoxycholate formulation of amphotericin B. However, serious side effects are associated with this drug. This study found that liposomal amphotericin B was less toxic than amphotericin B and was associated with improved survival.
Ann Intern Med. 2002;137(2):105-109. doi:10.7326/0003-4819-137-2-200207160-00008
U.S. Preventive Services Task Force*
The U.S. Preventive Services Task Force strongly recommends that clinicians routinely provide colorectal cancer screening for all adults 50 years of age or older.
Ann Intern Med. 2002;137(2):129-131. doi:10.7326/0003-4819-137-2-200207160-00014
Michael Pignone, MD, MPH; Melissa Rich, MD; Steven M. Teutsch, MD, MPH; Alfred O. Berg, MD, MPH; Kathleen N. Lohr, PhD
This systematic review supports the U.S. Preventive Services Task Force's position on screening for colorectal cancer.
Ann Intern Med. 2002;137(2):132-141. doi:10.7326/0003-4819-137-2-200207160-00015
David W. Bates, MD, MSc*
This article analyzes the case of a patient with iatrogenic hypoglycemia due to administration of the wrong medication. The institution's “root-cause analysis” of the factors contributing to this particular adverse event and the institution's response are discussed, and the literature on preventing medication errors is reviewed.
Ann Intern Med. 2002;137(2):110-116. doi:10.7326/0003-4819-137-2-200207160-00009
Joanne Lynn, MD; Kevin Nolan, MA; Andrea Kabcenell, RN, MPH; David Weissman, MD; Casey Milne, RN, BSN, CCM, CMC; Donald M. Berwick, MD; for the End-of-Life Care Consensus Panel*
Most people in developed countries will live with a serious, eventually fatal, chronic condition for months or years before dying, yet the delivery of health care services has only recently begun adapting to this reality. Lynn and colleagues discuss a composite case study in a nursing home setting, which builds on experience with multisite collaborative efforts and introduces quality improvement methods in the context of end-of-life care.
Ann Intern Med. 2002;137(2):117-122. doi:10.7326/0003-4819-137-2-200207160-00010
Lindsey R. Baden, MD; Robert H. Rubin, MD
The management of the patient with cancer who has chemotherapy-induced neutropenia and fever has changed markedly over the past four decades. Empirical antimicrobial therapy is now the standard of care for any patient with cancer and neutropenia who has unexplained fever, rigors, or subtler signs of sepsis. The study by Peacock and colleagues in this issue adds significantly to our understanding of the effect of this approach in patients with cancer.
Ann Intern Med. 2002;137(2):123-124. doi:10.7326/0003-4819-137-2-200207160-00011
Sanjay Saint, MD, MPH; Benjamin A. Lipsky, MD; Susan Dorr Goold, MD, MHSA, MA
More than four decades ago, Dr. Paul Beeson persuasively argued against routine use of indwelling urinary catheters in hospitalized patients, making the “case against the catheter.” This advice remains relevant today.
Ann Intern Med. 2002;137(2):125-127. doi:10.7326/0003-4819-137-2-200207160-00012
Neil Nakadate, PhD
My father's precise, thorough ways as a fly fisherman told you what to expect of his ways in the practice of anesthesiology.
Ann Intern Med. 2002;137(2):142. doi:10.7326/0003-4819-137-2-200207160-00016
Ann Intern Med. 2002;137(2):143. doi:10.7326/0003-4819-137-2-200207160-00017
Ann Intern Med. 2002;137(2):143. doi:10.7326/0003-4819-137-2-200207160-00018
Ann Intern Med. 2002;137(2):143-144. doi:10.7326/0003-4819-137-2-200207160-00019
Ann Intern Med. 2002;137(2):144. doi:10.7326/0003-4819-137-2-200207160-00020
Ann Intern Med. 2002;137(2):144. doi:10.7326/0003-4819-137-2-200207160-00021
Ann Intern Med. 2002;137(2):144-145. doi:10.7326/0003-4819-137-2-200207160-00022
Ann Intern Med. 2002;137(2):145. doi:10.7326/0003-4819-137-2-200207160-00023
Ann Intern Med. 2002;137(2):145-146. doi:10.7326/0003-4819-137-2-200207160-00024
Ann Intern Med. 2002;137(2):146-147. doi:10.7326/0003-4819-137-2-200207160-00025
Ann Intern Med. 2002;137(2):147. doi:10.7326/0003-4819-137-2-200207160-00026
Loreen Herwaldt, MD
Ann Intern Med. 2002;137(2):128. doi:10.7326/0003-4819-137-2-200207160-00013
Ann Intern Med. 2002;137(2):I-20. doi:10.7326/0003-4819-137-2-200207160-00001
Ann Intern Med. 2002;137(2):I-24. doi:10.7326/0003-4819-137-2-200207160-00002
Ann Intern Med. 2002;137(2):I-38. doi:10.7326/0003-4819-137-2-200207160-00003
Ann Intern Med. 2002;137(2):I-54. doi:10.7326/0003-4819-137-2-200207160-00004
Catherine V. Caldicott, MD
Ann Intern Med. 2002;137(2):148. doi:10.7326/0003-4819-137-2-200207160-00027
Rita Charon, MD, PhD
Ann Intern Med. 2002;137(2):148. doi:10.7326/0003-4819-137-2-200207160-00028
Ann Intern Med. 2002;137(2):No Pagination Specified. doi:10.7326/0003-4819-137-2-200207160-00029
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only